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Abstract: Tumor progression associated with hematogenous metastatic spread is a multistep process
based on a cross-talk between tumor and stromal cells in a tumor microenvironment. In the blood
circulation, tumor cells interact with blood cells through receptors such as selectin and integrins that
promote tumor cells survival. At the metastatic sites, heparanase secreted by tumor or stromal cells is an
important modifier of the tumor microenvironment while promoting tumor invasiveness and angiogenesis.
Heparin, particularly low molecular weight heparin, is used for treatment of cancer patients with evidence
of hypercoagulability. However, in preclinical studies heparins was shown to contain other biological
activities that affect cancer progression including inhibition of heparanase, selectins and integrins. While
ongoing clinical trials are assessing inhibition of heparanase on cancer progression, the remaining biological
activities of heparins inhibiting cells adhesion, through selectins and integrins remains largely unexplored.
This chapter addresses the potential role of heparins in oncology with respect to their anti-heparanase
and anti-adhesive activities and aims to discuss aspects relevant for broader therapeutic application of
heparins.
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Cancer progression – metastasis is a process encompassing multiple steps including successful escape 
of tumor cells from the primary tumor sites, survival in the circulation, evading immune responses, seeding 
in distant organs, and most importantly initiation and a sustained growth at these sites. Even though 
sustained proliferation of tumor cells is likely the most fundamental trait in tumor cells, the capacity to 
“modulate” the tumor microenvironment consisting of non-tumorigenic stromal cells significantly 
contributes to metastasis, virtually at every step of this process (1, 2). Particularly, the capacity of tumor 
cells to secrete extracellular matrix degrading enzymes, such as heparanase or proteases, profoundly 
contribute to migratory properties of tumor cells, or to the release of factors promoting tumor growth and 
angiogenesis (3, 4).  
Heparanase expression is linked to an invasive phenotype of a variety of cancer types in patients and 
has been confirmed in numerous animal models (3, 5, 6). This book covers all known aspects of heparanase 
biology in great details, thus the focus of this chapter is on heparanase action in leukocyte recruitment 
and cell-cell interactions during cancer progression. In addition, the activity of heparin and heparin 
derivatives on cancer progression will be discussed with respect to their anti-heparanase and anti-adhesive 
activities; and current developments towards therapeutic applications.  
 
Cell adhesion promotes tumor cell and leukocyte migration 
The immune system "responds" only when leukocytes are able to cross blood vessels. Circulating 
leukocytes do not interact with the endothelial cells. Endothelial activation is required to initiate leukocyte 
adhesion and to enable the migration of leukocytes through the endothelium. The formation of chemokine 
gradient is a prerequisite for driving the cell recruitment and the capacity of cells to adhere to the vessel 
wall and to initiate trans-endothelial migration (7). Selectins are likely the first cell adhesion molecules 
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involved in leukocytes recruitment and transendothelial migration. Inflammatory stimuli activate 
endothelial cells that increase expression of adhesion molecules including P-selectin, E-selectin and 
increases vascular permeability (8, 9). Interactions of vascular selectins with their ligands lead to the 
leukocyte rolling on activated endothelium, followed by integrin-mediated firm adhesion and finally 
leukocyte extravasation into the parenchyma, where leukocytes can execute their effector functions (10).  
Extravasating leukocytes need to engage the endothelium, and after diapedesis they face the 
basement membrane surrounding most of postcapillary venules, which is a complex meshwork of 
collagens interconnected with glycosaminoglycans, such as heparan sulfate. Heparanase is a hydrolytic 
enzyme enabling degradation of heparin sulfate, thus likely promoting leukocyte migration after 
extravasation (11, 12). Interestingly, neither neutrophils nor T cells require heparanase expression for an 
efficient extravasation as has been shown using heparanase deficient mice (11). On contrary, efficient 
monocyte extravasation required heparanase expression, in a peritoneal inflammation model. In the 
pulmonary vasculature, which represents the largest capillary bed in our body, the transendothelial 
migration of neutrophils also does not require heparanase expression (12). However, in chronically 
inflamed lungs, neutrophil accumulation required heparanase, while T cell recruitment remained 
heparanase independent but was mediated by ICAMs instead. Thus, on contrary to tumor cells, where 
enhanced heparanase expression is linked to an invasive behavior, leukocyte transendothelial migration 
does not require heparanase.  
During cancer metastasis selectin-mediated interactions were shown to be essential for the 
recruitment of myeloid cells and monocytes that enhances tumor cell extravasation and facilitate 
metastasis in several mouse models. The metastatic microenvironment further promotes recruitment of 
monocytes and myeloid cells through enhanced presence of chemokines, e.g. CCL2, CCL5 (9, 13). These 
observations show that metastatic tumor cells “highjack” the physiological function of selectins and 




Cell adhesion as determinant of metastasis 
Cell adhesion defines the physiological function of any cell in the body through contacts to other 
cells or to extracellular matrix (ECM) component within the tissue environment. Since cell adhesion is 
connected to the signal-transduction pathways affecting cell phenotype, survival, differentiation and 
migration, alteration in cell adhesion frequently observed in tumor cells directly contributes to cancer 
progression. During cancer progression several families of adhesion molecules including: cadherins, 
integrins, junctional-adhesion molecules, and selectins have been studied. The topic of cell adhesion in 
cancer progression is too extensive to be covered in this chapter and excellently reviewed elsewhere (14, 
15). Thus, we focus on the role of cell adhesion in steps of metastasis in context of potential involvement 
of heparanase.  
Hematogenous metastasis is a highly orchestrated process describing the ability of tumor cells to 
enter in the blood circulation, survive the circulation and extravasate in secondary sites, where they can 
form metastases. Tumor cells in circulation undergo multiple interactions with blood cellular components, 
such as platelets and leukocytes that are essential for tumor cell survival and further for metastasis. Two 
major families of cell adhesion molecules, selectins and integrins, have been identified to facilitate cell-
cell interactions essential for the metastatic spread (reviewed in (10, 16-19). Here we will discuss selectins 
and integrins both as mediators of metastasis and as targets of heparin-based therapeutic approaches.  
Selectin as mediators of metastasis 
Selectins have been identified as key adhesion molecules that mediate adhesive events between 
leukocytes, endothelial cells and platelets during leukocyte trafficking and hemostasis (20). There are three 
members of the selectin family: P-, L- and E-selectin. Platelets and endothelial cells express P-selectin that 
is stored in α-granules and Weibel-Palade bodies, respectively; and upon activation rapidly translocates 
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on the cell surface of these cells. E-selectin is expressed in endothelial cells, where upon activation a de 
novo transcription is initiated, and its cell surface expression lasts longer than of P-selectin. L-selectin is 
constitutively expressed on cell surfaces of almost all leukocyte subpopulations (21). Selectins mediate 
adhesion by heterotypic interactions of their C-type lectin domain with glycan-bearing ligands. The 
minimal recognition motif for all selectins is the sialyl-Lewisx sLex and its isomer sialyl-Lewisa (sLea) 
tetrasaccharide that is sequentially synthesized by N-acetyl-glucosaminyltransferases, 
galactosyltransferases, α1,3-fucosyltransferases IV or VII, and α2,3-sialyltransferases (10, 21). Due to the 
relatively low binding affinity towards a single carbohydrate domain, physiological ligands represent a 
scaffold of clustered domains to increase the avidity of binding. In addition, P- and L-selectin, but not E-
selectin, can bind to sulfated glycans including heparin, heparan sulfate, fucoidan and sulfated glycolipids 
(22), indicating that selectins recognize rather a carbohydrate “patch” generated in different ways.  
The relevance of selectin involvement in hematogenous metastasis has been deduced from the 
observations that particularly epithelial cancers, carcinomas undergo profound changes in cell-surface 
glycosylation (23, 24). The cancer-induced aberrant glycosylation often goes along with enhanced 
presence of selectin ligands enabling tumor cells to interact with other blood constituents once they enter 
the blood circulation (23). Selectin-mediated interactions of tumor cells with leukocytes, platelets and 
endothelial cells provide a mechanistic explanation for the clinical association with poor prognosis for 
cancer patients (23, 25, 26). Tumor cells in blood circulation are often covered by platelets, as has been 
observed in patients and animal models. The first evidence that this platelet-tumor cell interaction is P-
selectin dependent has been described in a mouse model with P-selectin deficiency (27). Platelet’s P-
selectin bound to carcinoma mucins, since glycan removal inhibited platelet-tumor cell interaction and 
thus also metastasis (28). The role of platelets in malignancy and metastasis has been thoroughly 
investigated since then and is excellently reviewed elsewhere (29-31). Of note, P-selectin expression on 
endothelial cells also contributes to metastasis as has been shown in bone marrow reconstituted P-
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selectin-deficient mice (32). Similarly, E-selectin has been associated with formation of a premetastatic 
niche, where the recruitment of tumor cells as well as myeloid-derived cells facilitates metastasis (33, 34). 
Interestingly, the endothelial activation is essential for the recruitment of monocytes and tumor cell 
extravasation (9, 35). 
Leukocytes are a key component of the tumor microenvironment and they exert many activities 
promoting metastatic dissemination and metastatic niche formation. Particularly, myeloid-derived cells 
such as monocytes and neutrophils expedite tumor cell extravasation and formation of metastatic niche 
(36-38). L-selectin facilitates the recruitment of myeloid cells to tumor cells in circulation and enables their 
extravasation through the endothelial cells (13, 39). The inhibition or the absence of L-selectin resulted in 
attenuation of metastasis due to the lack of leukocyte-induced endothelial activation (9, 13). There is little 
knowledge about the role of L-selectin on lymphocytes in cancer progression, despite the canonical 
function of L-selectin in facilitating of lymphocytes recruitment into lymph nodes (21). In an inflammation 
model, L-selectin was shown to mediate the recruitment of activated CD8+ T cells to virus-infected organs 
and thereby confers protective immunity (40). Whether L-selectin facilitates activated cytotoxic CD8+ T cell 
recruitment during tumor progression remains unclear.  
 
Selected aspects of integrins during cancer metastasis 
Integrins are ubiquitously expressed trans-membrane glycoproteins with important functions in 
cellular adhesion and signaling. The structure of integrins comprises a non-covalently bound heterodimers 
with α- and a β-subunit. 18 α- and 8 β-integrin subunits have been characterized that combine to form 24 
unique canonical α/β receptors identified so far. Integrins mediate cell adhesion, primary to components 
of the ECM, such as fibronectin, vitronectin, laminin, or collagen, thus contributing to cellular anchorage 
but also to cell motility and invasion. Furthermore, integrins also mediate certain aspects of cell-cell 
7 
 
interactions relevant for tumor cell metastasis. Integrins are important mediators of a bidirectional cellular 
signaling due to their anchorage to the cytoskeletal structures (e.g. α-actinin, talin, and vinculin). As a 
consequence, ligation of extracellular ligands can influence intracellular processes (outside–in signaling) 
through activation of kinases, GTPases of the Ras/Rho signaling pathways. On contrary, intracellular signals 
can induce alterations in the integrin conformation and thus change ligand-binding properties (inside–out 
signaling).  
An immense body of knowledge has been accumulated covering the multiple roles of integrins in 
oncology and tumor cell metastasis recently reviewed (41). To name just few aspects of integrin-triggered 
interaction during metastasis, integrins mediate: growth factor receptor signaling (42), tumor cell 
chemoresistance (43), epithelial to mesenchymal transition (44) and angiogenesis (45). For further details 
we refer the readers to excellent reviews in this field (41, 46). In general, the expression pattern of 
integrins has been associated with the malignant progression of certain tumors and correlated with altered 
patient’s survival. In this context, we will address here only the functions on integrins, which are directly 
related to cell-cell interaction during metastasis and discuss the potential targets for heparin to interfere 
in these processes. 
The role of platelet in cancer metastasis has been outlined regarding of P-selectin. However, 
platelets also express five different integrins, which contribute to the formation of tumor cell-platelet 
emboli during metastasis (47). For instance, α6β1 and αIIbβ3 integrins are directly involved in platelet 
adhesion to tumor cells and pharmacological interference with these integrins resulted in attenuated 
metastasis (48, 49). The α4β1integrin, very-late antigen-4 (VLA-4), is found on many cells of hematopoietic 
origin referring to their role in immune response by binding to the endothelial ligand VCAM-1. In addition, 
VLA-4 is also aberrantly expressed and active in different tumor types, such as melanoma (50). The current 
evidence show that VLA-4 facilitates melanoma cell binding to activated endothelial cells expressing 
VCAM-1 at distant sites; and the interference in VLA-4 attenuates melanoma metastasis in different model 
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systems (51-54). Furthermore, the aberrant expression of the VLA-4 ligand, VCAM-1, by certain tumor cells 
was shown to mediate trafficking and binding of macrophages into the forming micrometastases and 
thereby promotes the formation of a permissive microenvironment for tumor cell outgrowth (55). 
Integrins have recently been identified to contribute to organ-specific metastasis through their expression 
on tumor-derived exosomes (56). Proteomic analysis of tumor-derived exosomes with tropism towards 
lungs and liver were shown to express predominantly the integrins α6β4 and α6β1 (lungs) and αvβ5 (liver), 
driving the formation of a pre-metastatic niche in the respective organ. 
Taken together, selectin and integrin adhesion receptors promote cancer progression through various 
mechanisms (reviewed in (16). As a consequence, a pharmacological interference with adhesion receptor 
activities remains an attractive option to attenuate metastasis. Although the inhibition of selectins in 
experimental settings has been efficient in numerous cancer models, there are no clinical studies focusing 
on selectins. In case of integrins, the ubiquitous expression of the different integrin subtypes and partly 
overlapping ligand recognition complicate a specific targeting. Interestingly, heparin and heparin 
derivatives have been shown to inhibit P- and L-selectin as well as VLA-4 integrin in experimental settings. 
Since heparins are currently used in treatment of cancer patients with thrombosis, the question remain to 
which extent heparin may affect cell adhesion or heparanase activity during metastasis. 
 
Heparin as inhibitor of cell adhesion 
Heparin, low-molecular weight heparin (LMWH) and heparin derivatives (further named as 
heparins) were tested in many different animal models for its potential to attenuate cancer progression 
(reviewed in e.g. (57, 58). Interestingly, various heparins tested in animal models have shown primarily 
attenuating effect on metastasis rather than tumor growth. Most of these studies were performed in an 
experimental metastasis model where tumor cells were directly injected into the blood circulation. Despite 
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many limitations of this experimental approach, the timely defined presence of tumor cells in the 
circulation has allowed the evaluation of cellular and molecular mechanisms during the hematogenous 
phase of the metastasis. A variety of heparins efficiently reduced cancer progression when applied shortly 
before or shortly after the intravenous injection of tumor cells (57). However, the application of heparin 
twenty four hours before or after the tumor cell injection had no effect on metastasis (32, 59). While in 
the majority of early studies heparins were used at concentrations exceeding the therapeutic dosage rage, 
later publications have confirmed the efficacy of heparin to inhibit metastasis also at clinically relevant 
concentrations (60, 61). The fact that heparins showed anti-metastatic activity only when tumor cells were 
still in circulation strongly indicate that cellular and molecular events occurring during this phase are 
potential targets of heparin instead of solely affecting the coagulation pathway (16, 26). This conclusion is 
further supported by the observation that half-life of heparin in circulation is rather limited, not exceeding 
six hours, thus affecting processes like angiogenesis or tumor growth less likely.   
Heparin is a complex natural glycosaminoglycan extracted from porcine intestine, which in clinical 
preparation is enriched for the ability to inhibit the clotting cascade. In addition, heparins have a wide 
variety of potential biological effects including the ability to: interact with integrins, inhibit P- and L-selectin 
interactions, inhibit heparanase, attenuate angiogenesis; and affect growth factors and chemokines (26, 
62). Despite these many potential effects, experimental data indicate that heparins affect processes during 
the hematogenous phase of metastasis. Within blood vessels, circulating tumor cells ultimately interact 
with the endothelium and other blood constituents (e.g. platelets and leukocytes) that might lead to tumor 
cell arrest and extravasation also through increased heparanase activity. Thus, the antimetastatic activities 
of heparins were analyzed by various groups for their potential to affect coagulation, inhibit cell-cell 
interactions and to block heparanase as depicted in Figure 1 (reviewed in 63). Although the anticoagulant 
activity may contribute to reduced metastasis, several works clearly indicated that heparins without 
anticoagulant activity attenuated equally well cancer progression in various cancer entities; e.g. lung, colon 
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and breast cancers (reviewed in 64). The initial finding that P- and L-selectins can effectively bind to 
heparins (65, 66) initiated a series of studies testing the hypothesis that heparin treatment inhibits 
selectin-mediated interactions and thereby metastasis (28, 39, 60). In parallel, it was shown that integrin-
mediated interactions during inflammation can be inhibited by heparin (67, 68), suggesting that heparin 
may block also integrin-mediated interactions during metastasis. Indeed, heparin was shown to block 
αIIbβ3-integrin mediated interactions of platelets with melanoma cells (69). In another study, heparin was 
shown to block α4β1-integrin mediated adhesion of melanoma cells to the endothelium (70). Taken 
together, these studies provided a rationale to explore heparin as an inhibitor of cell adhesion during 
metastasis, albeit the heparanase-inhibitory activity remained to be answered. 
 
The role of heparin in cancer treatment - Clinical evidence 
The close relationship between cancer and hypercoagulability has been observed already in the 
19th century by the French physician Armand Trousseau (reviewed in (71, 72) and is under constant 
investigation since then (reviewed in (73, 74). Cancer patients with malignant diseases are at a higher risk 
of developing thromboembolic complications contributing to morbidity and mortality of the disease when 
compared to healthy population. This includes venous thromboembolism (VTE) which encompasses deep 
vein thrombosis (DVT) and pulmonary embolism (PE); and also arterial thrombosis. Cancer-associated 
thrombosis in numbers is reflected in six time higher chance to develop VTE compared to non-cancer 
subjects, that is further increased in patients receiving chemotherapy (75). Epidemiologically, about 15% 
of cancer patients will develop VTE, and about 20% of patients with VTE have an unknown neoplasm at 
the time of diagnosis. Consequently, VTE complications contribute significantly to morbidity and mortality 
of cancer patients, where VTE is the second leading cause of death. There are several mechanisms being 
identified to be involved in cancer-triggered thromboembolism enabling development of specific therapies 
(reviewed in 72, 75).  
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Antithrombotic prophylaxis or treatment is an essential component of clinical therapy especially 
for patient populations with an increased risk to develop VTE. A multitude of studies and meta-analyses 
have been performed to define an optimal pharmacological interference with the activated hemostatic 
system in cancer diseases (reviewed in (63)). The treatment guidelines of first-line therapy for the short- 
and long-term management of cancer associated VTE, including these of the European Society of Medical 
Oncology (ESMO), the National Comprehensive Cancer Network (NCCN), or the American Society of 
Clinical Oncology (ASCO) currently recommend LMWH as first choice (76, 77). The clinical handling of 
LMWH in oncology is experienced for several decades and displays a balanced safety profile, e.g. 
superiority over vitamin K antagonists. The guidelines recommend the treatment of acute symptomatic 
VTE by LMWH for longer time periods, up to six months. In terms of VTE prophylaxis, LMWH is also 
guideline-based recommended for certain cancer patients for short term application (78). Although 
heparin and particularly LMWH are used for treatment of cancer patients with thrombotic complication 
for decades, the question, whether heparin treatment has other anti-cancer activities, going beyond 
anticoagulation, remains open.   
A potential antitumor effect of an antithrombotic treatment using heparin and LMWH has been 
suggested based on several retrospective and prospective clinical trials of cancer patients at risk of VTE 
(summarized in 79). A number of controlled prospective studies in the early 2000 years showed promising 
results especially in patients with early, non-metastatic stage of the disease. While there was no effect on 
overall survival in variety of solid tumors, the analysis of a subset of patients, who were metastasis-free at 
the beginning of the trial, demonstrated a significant increase in survival with the LMWH dalteparin in that 
population (80-83). An open-label controlled study in small cell lung cancer patients, receiving standard 
treatment plus/minus LMWH in a therapeutic dose for 18 weeks, showed a significant increase in the 
overall survival and progression free survival in the treatment arm (84). A comprehensive review on all 
clinical trials conducted by 2007 has been re-evaluated that confirmed certain benefits for LMWH-treated 
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cancer patients especially in the early stage of lung cancer (85). Nonetheless, several further clinical studies 
could not, or not completely confirm this beneficial LMWH effect on overall survival, while the reduction 
in the VTE as a primary endpoint by LMWH was significant (86-88). Three of these studies have been 
performed in non-small cell lung cancer patients using three different LMWH preparations: nadroparin, 
dalteparin and tinzaparin, respectively (86, 87, 89).  
The reasons for this non-favored outcome in light of LMWH are likely multifaceted due to 
methodological issues, tumor entities, or treatment regimens; and the use of different LMWH 
preparations. Furthermore, it remains open to which extend the chemotherapy, which was given in 
parallel, interferes with any effect of LMWH on patient’s survival. Finally, it needs to be considered that all 
LMWH preparations are tested only for anticoagulant activity, but not for the other biological activities, 
such as inhibition of cell adhesion or heparanase. There is a considerable difference in effectiveness of 
different LMWH preparation on cell adhesion and subsequently on metastasis as tested in preclinical 
models (60). Nevertheless, further studies on LMWH are warranted to address the question, how heparins 
affect cancer progression, beyond coagulation. The design of a clinical study should take into account the 
biological activity of heparins that has been proven in numerous preclinical studies.  
 
 
Heparanase – another player in cancer progression 
Heparanase (HPSE), an endoglycosidase, is the sole enzyme in mammalian organisms able to 
cleave heparan sulfate (HS) chains into HS fragments (90). HS macromolecules have an essential role in 
cell signaling and communication, primarily due to their capacity to bind to growth factors and cytokines 
and thereby creating a reservoir of signaling molecules in the ECM and on the surface of cells. Thus, the 
capacity of HPSE to degrade HS has important implications for remodeling of the cellular 
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microenvironment as has been shown during inflammation and cancer progression (91). HSPE affects 
tumor growth and metastasis in various ways, e.g. by fostering tumor cell extravasation, angiogenesis etc. 
(discussed in other chapters of this book). Many types of cancer show upregulated expression of HPSE that 
is a marker of poor prognosis in cancer patients (92). Experimental evidence using transgenic expression 
of HPSE both in tumor cells or in mice as well as HPSE knock-down methods convincingly linked HPSE to 
metastasis (93, 94). Interestingly most but not all activities of HPSE during tumorigenesis and metastasis 
were shown to be related to the enzymatic functionality altering the tumor microenvironment. Here we 
briefly recapitulate the most important aspects of HPSE with respect to metastasis, while a thorough 
discussion of HPSE protumorigenic activities can be found in other chapters of this book and are reviewed 
elsewhere (5, 95). 
The enzymatic function of HPSE was shown to promote tumor angiogenesis and production of 
exosomes that significantly contribute to formation of metastasis (96, 97). Recently it was shown that 
HPSE-mediated shedding of syndecan-1 liberates peptide fragments with VEGF receptor activity (98). 
Exosomes are dominant mediators of intercellular communication that drive metastasis by regulating the 
tumor-host cell interactions both locally within the tumor microenvironment and distally at metastatic 
sites (99). The enhanced expression of HPSE in human cancer cells, as well as tumor cell exposure to 
exogenous HPSE possibly derived from the tumor microenvironment, was shown to dramatically increase 
exosome secretion through a modulation of syndecan-1 signaling (97, 100). This process relies on the HPSE 
enzymatic cleavage of heparan sulfate, and also impacts exosome protein cargo as reflected by higher 
levels of syndecan-1, VEGF and HGF (97). HPSE was identified as a key factor in myeloma cells driving 
survival and resistance against chemotherapy via activating the ERK signaling pathway (101). Treatment 
of colon carcinoma cells with heparanase induced expression of inflammatory cytokines such as CCL2, 
CCL5 and CXCL1, indicating that heparanase from stromal cells has the capacity to directly activate tumor 
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cells and thereby modulate the tumor microenvironment (102). Similarly, heparanase activity was shown 
to activate macrophages in a tumor microenvironment through the Erk, p38 signaling pathway (103). 
With respect to non-enzymatic activity of HPSE, latent HPSE induces adhesion receptor activity for 
spreading or migration of different tumor cell types by inducing a signaling axis via binding and clustering 
the cellular HSPGs (reviewed in 3). Latent HPSE facilitates integrin binding and thereby promotes adhesion 
and metastasis of melanomas, which can be antagonized by LMWH (104). Interestingly, latent HPSE on 
endothelial and cancer cells induces tissue factor (TF) expression and thus contributes to coagulation 
(105). Furthermore, the latent HPSE binds and displaces tissue factor pathway inhibitor from the 
endothelial surface as yet another way to modulate thrombosis in cancer (106). 
The multiple functional mechanisms how HPSE facilitates tumor progression and metastasis make 
it an excellent target for pharmacological inhibition. Manifold experimental approaches exist at the 
preclinical and even clinical level to affect HPSE in a therapeutic perspective. Not surprisingly, heparins 
have been one of the first targets tested in many in vitro and in vivo models.    
 
Heparin as an inhibitor of heparanase in metastasis 
The role of ECM-bound or cell surface-bound proteoglycans in cancer progression has granted the 
development of HPSE inhibitors on the basis of heparin structure. Structural evaluations have led to 
identification of two high affinity heparin recognition domain of HPSE, one closed to the N-terminus of the 
enzyme, where blockade of binding to heparin inhibits the enzymatic activity (107). Meanwhile, in 2015 
the crystal structure of HPSE has been resolved providing a further insight into the mapping of substrate 
recognition sites (108). 
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Heparin has served as a structural scaffold for optimization of the structural requirements for the 
development of glycosidic inhibitors of HPSE. First structural modifications of heparin identified the 
requirements for sulfation and N-acetylation to differentiate between anticoagulant and HPSE inhibitory 
properties of heparin during hemostasis (109, 110). Later on, the capacity of heparin and heparin 
derivatives to attenuate the lung colonization by melanoma cells has been confirmed using experimental 
metastasis approach in mice (59). The effectivity of heparins to attenuate metastasis was restricted to a 
short time period shortly before and several hours after tumor cell inoculation, which was considered to 
inhibit predominantly the tumor cell-derived HPSE during this phase. Another group has confirmed the 
impact of sulfation degree of heparin derivatives on HPSE inhibition in the same melanoma experimental 
metastasis model (111). Notably, in this study, the opening of the iduronic acid ring by oxidative/reductive 
procedures has been prepared and tested for its HPSE inhibitory activity. This approach has been later 
identified as one of the key methods to optimize heparin for its HPSE inhibitory activity (112).  
A comprehensive library of heparin derivatives as potential HPSE inhibitors has been assessed in 
vitro (112). The essential structural requirements of heparin for HPSE inhibition has been linked to its 
sulfation grade. A partial N-desulfation (replaced by acetylation) is well tolerated and considered as a 
discriminating factor between anticoagulant and HPSE-inhibiting activity of heparin. However, the 
preparation of a series of glycol-splitting derivatives (RO-heparins) with various degrees of N-desulfation 
resulted in identification of highly efficient compounds (112). These derivatives were used as scaffolds for 
development of HPSE-specific inhibitors (outlined in the chapter number 35 of this book) such as 
roneparstat that has been tested in multiple myeloma patients (113). The elimination of conformational 
restrains by glycol-splitting of the iduronic acid leads to rotational freedom of the heparin molecule, which 
together with N-acetylation strongly enhanced HPSE binding and thereby inhibitory potential. The 
structural modifications of heparin discussed with respect to all discussed biological activities are 
schematically shown in Figure 2. A further insight into the role of structural flexibility of glycol-split 
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derivatives has recently been given by a NMR-based conformational analysis and molecular dynamic study 
(114).  
Glycol-split heparin derivatives with various degree of N-desulfation/N-acetylation have been 
tested for their antimetastatic activity (115). RO-heparin as a specific inhibitor of HPSE inhibited melanoma 
metastasis, while had little effect on colon carcinoma metastasis. Interestingly, melanoma cells express 
high levels of HPSE while there was little expression detected in colon carcinoma cells, indicating the 
efficacy of HPSE inhibition only in cancers associated with high HPSE expression. Further studies 
investigated heparin-like polymers from mollusk origin for their capacity to inhibit HPSE besides other 
potential targets and thereby metastasis (116). Novel strategies developing HPSE inhibitors based on 
heparin-like structures resulted in preparation of a glycopolymer with specific sulfation pattern to be 
active in attenuating breast cancer metastasis (117).  
Several preclinical studies using a variety of animal models confirmed the role of HPSE in 
metastasis (reviewed in 64, 118). Based on many studies developing heparin-based inhibitors of HPSE 
without anticoagulant activities resulted in development of two drugs: roneparstat and necuparanib, that 
are currently in clinical trials as a treatment of cancer with enhanced HPSE activities (113, 119). The 
relevance of HPSE inhibition and its impact on cancer progression is clearly defined. Nevertheless, heparin-
based inhibitors require further analysis to determine the contribution of other biological activities (e.g. 
cell adhesion) to anti-metastatic activity.  
 
Dissecting the role of heparin in cancer progression 
Heparin and its derivatives are being studied for their potential to treat cancer in numerous 
preclinical models, and the results of these studies clearly indicate the capacity of heparin to inhibit cancer 
progression independently of its anticoagulant activity. Since heparin, particularly LMWH, is still used for 
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treatment of cancer patients with thrombotic complications, and based on several studies is associated 
with prolonged survival of some patient groups, heparin remains an attractive option for further 
development. Many pre-clinical studies have shown that heparin derivatives, or non-anticoagulant 
heparin-based analogues attenuate metastasis irrespective of an animal model or cancer entity (59, 60, 
115, 120-122). As discussed in this chapter inhibition of cell adhesion and of HPSE are likely the two 
biological activities contributing most significantly to inhibition of cancer progression. While several 
studies characterized heparin derivatives for their HPSE-inhibitory activity (e.g. 59, 120), other studies 
evaluated the selectin inhibitory activity (28, 60). Later on, heparin derivatives were tested for both HPSE 
and selectin-inhibitory activity using experimental metastatic mouse models (115, 122). The selectin-
specific heparin derivative (57% N-acetylated-heparin) attenuated metastasis both with colon carcinoma 
and melanoma cells (115). On contrary, HPSE specific heparin derivative (100% N-acetylated glycol-split 
heparin) effectively inhibited melanoma metastasis, but was ineffective for attenuation of colon 
carcinoma metastasis. When we used semisynthetic sulfated trimannose C-C dimers, HPSE specific 
derivative again attenuated only melanoma metastasis, while selectin specific-derivative inhibited both 
melanoma and colon carcinoma metastasis (122). Although melanoma cells (B16-BL6) expressed 
significant amounts, colon carcinoma cells (MC-38) showed low amounts of HPSE (115). Of note, many 
tumor cells tested express high levels of HPSE (115, 123, 124). Taken together, these studies provided 
evidence that heparin-based selectin inhibition attenuated metastasis in both tested cells, while the 
inhibition of HPSE affected metastasis of those tumor cells with enhanced HPSE activity. 
In a recent work, the HPSE-neutralizing antibody has been tested as inhibitors of cancer 
progression using Burkitt’s lymphoma and glioma cells (123). While Raji cells do not produce any 
detectable HPSE activity, the anti-HPSE antibody significantly reduced tumor growth and metastasis of 
these cells. These findings indicate that heparanase derived from the tumor microenvironment is 
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significantly contributing to the tumor growth (123). Since primary tumor growth was significantly 
attenuated in this model, the specific role of heparanase inhibition on metastasis could not be addressed.  
 
Conclusions 
Metastasis is in ninety percent of cancer patients the ultimate cause of death, yet there is no 
specific anti-metastatic therapy currently available. Based on the current understanding of metastasis, 
invasiveness and mechanisms related to tumor cell survival, HPSE; as the principal modifier of the tumor 
microenvironment and invasiveness; and cell adhesion mechanisms enabling tumor cell interactions with 
the other cells during transition, offers the best targets for exploration of future therapies. While specific 
targeting of HPSE, based both on heparin-glycomimetics and specific antibody-based therapies are 
ongoing, particularly in hematopoietic malignancies (5, 123, 125), there is little progress on cell adhesion-
based approaches. However, heparin derivatives have been extensively studied for their capacity to 
interfere with cancer progression (reviewed in 10, 16, 26).  
As discussed in this chapter, heparin carries several biological activities that are beneficial for 
attenuation of metastasis. In fact, most of heparin preparations used both in preclinical and clinical studies 
carried out thus far contained various activities such as HPSE and selectin-inhibitory activity. Yet, only the 
anti-coagulation and HPSE activity of heparin was mostly assessed. Despite of many studies, the 
identification of the critical biological activities of heparin for its anti-metastatic behavior is still not 
possible, largely due to the fact that heparin has not been vigorously tested for all or at least several known 
activities. Clearly, it is of scientific interest to dissect the role of heparin as an inhibitor of cancer 
progression, but from the clinical perspective, inhibition of multiple mechanisms involved in cancer 
progression by heparin might prove beneficial for the cancer patient. Thus, further clinical studies designed 
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Figure 1  Heparin contains diverse biological activities that affects cancer progression. The main three 
biological activities affections heparanase (HPSE), coagulation and cell adhesion as discussed in this 
chapter. In addition, heparanase positively influences primary tumor growth through promotion of 
angiogenesis, and extracellular matrix remodeling associated also with a release of growth factors. Many 
of these activities have been confirmed in vitro and in vivo. A direct effect of heparin on metastasis has 





Figure 2.  Structural modifications of heparin and their impact on relevant targets during tumorigenesis 
and metastasis. The anticoagulant activity of heparin is strongly attenuated or minimalized by 2O- or 6O-
desulfation; or by opening the iduronic acid ring (glycol-split heparin/RO-H), inhibitory capacity towards 
HPSE, P- and L-selectin or the integrin VLA-4 are largely preserved. Notably, N-acetylation of glycol-split 
heparin (NA-RO-H) appears to be a key to differentiate HPSE-inhibitory potential from the other targets.  
 
